Form 4: Upstream Bio General Counsel Sells Shares for Tax Cover

Upstream Bio's General Counsel, Allison Ambrose, sold 475 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Allison Ambrose, General Counsel of Upstream Bio, Inc. (UPB), reported a transaction involving the company's common stock.
• On March 16, 2026, Ambrose disposed of 475 shares of common stock at a price of $9.29 per share.
• The sale was executed under a "sell-to-cover" policy to satisfy tax withholding obligations associated with the vesting of restricted stock units.
• This transaction was automatic and not at the discretion of Allison Ambrose.
• Following the reported transaction, Allison Ambrose beneficially owns 16,525 shares of Upstream Bio common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine, non-discretionary transaction for tax purposes and does not reflect a change in the insider's investment sentiment or the company's operational performance.

Positives

• The vesting of restricted stock units indicates that employee incentives are being realized, which can contribute to employee retention and alignment with company performance.

Negatives

• No direct negatives are identified from this routine, non-discretionary tax-related stock sale.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person.
• The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions are a standard practice in the industry for executives to meet tax obligations upon the vesting of equity awards. These transactions are typically non-discretionary and are generally not interpreted as a reflection of an insider's sentiment regarding the company's future prospects or a signal of fundamental changes.

Comparison to Industry Standards

• This 'sell-to-cover' transaction aligns with common corporate governance practices seen across publicly traded companies, where equity compensation plans include provisions for automatic share sales to cover tax liabilities upon vesting.
• Similar practices are observed in companies like Moderna (MRNA) or Pfizer (PFE) where executives frequently execute such sales for tax purposes without indicating a change in their long-term outlook on the company.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary tax-related sale and not indicative of a change in company fundamentals or insider sentiment.
• Employees: The vesting of restricted stock units generally has a positive impact on employee morale and retention by providing long-term incentives.

Key Dates

Recommendation

This Form 4 filing details a routine 'sell-to-cover' transaction by an insider to satisfy tax obligations on vested equity. Such non-discretionary sales are common and do not typically signal a change in the company's fundamental outlook or the insider's confidence. Therefore, it provides no new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation.

Keywords

Upstream Bio, UPB, Form 4, Insider Transaction, Stock Sale, Allison Ambrose, General Counsel, Sell-to-Cover, Restricted Stock Units, Tax Withholding